Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma: The Phase I–II Hydroxychloroquine-Transarterial Chemoembolization (qTACE) Trial
- 23 August 2024
- journal article
- editorial
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (1) , 175-178
Abstract
No abstract availableFunding Information
- AstraZeneca
- Department of Veterans Affairs (I01CX002542)
- Pfizer
This publication has 11 references indexed in Scilit:
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.Journal of Clinical Oncology, 2024
- Watch What You (Self-) Eat: Autophagic Mechanisms that Modulate MetabolismCell Metabolism, 2019
- PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in CancerCancer Discovery, 2019
- Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular CarcinomaRadiology, 2017
- Combined MTOR and autophagy inhibitionAutophagy, 2014
- The “stone-like” pattern of LC3A expression and its clinicopathologic significance in hepatocellular carcinomaBiochemical and Biophysical Research Communications, 2013
- Ammonia-induced autophagy is independent of ULK1/ULK2 kinasesProceedings of the National Academy of Sciences, 2011
- DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular CarcinomaThe American Journal of Pathology, 2011
- Hypoxia signalling through mTOR and the unfolded protein response in cancerNature Reviews Cancer, 2008
- A dose‐ranging study of the pharmacokinetics of hydroxy‐chloroquine following intravenous administration to healthy volunteers.British Journal of Clinical Pharmacology, 1988